ArticleInorganic chemistry2017
Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.
Article in Inorganic chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Article
- Transmetalation in Cancer Pharmacology.International journal of molecular sciences · 2025Review
- Water-Soluble, Titanocene-Based Prodrugs with Thiosemicarbazones as Cytotoxic Agents.ACS omega · 2025Article
- Deferasirox Derivatives as Inhibitors of Kallikrein-Related Peptidases Associated to Neurodegenerative Diseases.ChemMedChem · 2025Article
- Elucidating the High Affinity Copper(II) Complexation by the Iron Chelator Deferasirox Provides Therapeutic and Toxicity Insight.ChemMedChem · 2025Article
- Article
- Deferasirox's Anti-Chemoresistance and Anti-Metastatic Effect on Non-Small Cell Lung Carcinoma.Biomedicines · 2024Article
- Anticancer Metallocenes and Metal Complexes of Transition Elements from Groups 4 to 7.Molecules (Basel, Switzerland) · 2024Review
- Advantageous Reactivity of Unstable Metal Complexes: Potential Applications of Metal-Based Anticancer Drugs for Intratumoral Injections.Pharmaceutics · 2022Review
- Exploring Titanium(IV) Complexes as Potential Antimicrobial Compounds.Antibiotics (Basel, Switzerland) · 2022Article
- Article
- Article
- Using X-ray Diffraction Techniques for Biomimetic Drug Development, Formulation, and Polymorphic Characterization.Biomimetics (Basel, Switzerland) · 2020Review
- Design, Synthesis, Computational, and Preclinical Evaluation ofMolecules (Basel, Switzerland) · 2020Article
- Evaluating Ligand Modifications of the Titanocene and Auranofin Moieties for the Development of More Potent Anticancer Drugs.Inorganics · 2020Article
- Fueling a Hot Debate on the Application of TiOMaterials (Basel, Switzerland) · 2019Review
- Lactoferrin ameliorates dopaminergic neurodegeneration and motor deficits in MPTP-treated mice.Redox biology · 2019Article
- Iron in Neurodegeneration - Cause or Consequence?Frontiers in neuroscience · 2019Review
- Exploring titanium(IV) chemical proximity to iron(III) to elucidate a function for Ti(IV) in the human body.Coordination chemistry reviews · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
The recent X-ray structure of titanium(IV)-bound human serum transferrin (STf) exhibiting citrate as a synergistic anion reveals a difference in Ti(IV) coordination versus iron(III), the metal endogenously delivered by the protein to cells. This finding enriches our bioinspired drug design strategy for Ti(IV)-based anticancer therapeutics, which applies a family of Fe(III) chelators termed chemical transferrin mimetic (cTfm) ligands to inhibit Fe bioavailability in cancer cells. Deferasirox, a drug used for iron overload disease, is a cTfm ligand that models STf coordination to Fe(III), favoring Fe(III) binding versus Ti(IV). This metal affinity preference drives deferasirox to facilitate the release of cytotoxic Ti(IV) intracellularly in exchange for Fe(III). An aqueous speciation study performed by potentiometric titration from pH 4 to 8 with micromolar levels of Ti(IV) deferasirox at a 1:2 ratio reveals exclusively Ti(deferasirox)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.